SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr 23, 2012-- NextBio today unveiled NextBio Clinical, an extension of the company's existing life sciences platform to translational medicine applications such as biomarker discovery and clinical trial optimization. Adding curated genomic, molecular and clinical profiles from thousands of individual patients to the platform's existing repository of data from animal and cell line models, NextBio Clinical enables the earlier application of clinical information to enhance research and development.
"Since 2004, NextBio has been addressing the research needs of scientists at academic institutions, pharmaceutical and biotech companies with our cross-technology platform for integrative data analysis," says Saeid Akhtari, NextBio President and Chief Executive Officer. "Now, with NextBio Clinical, we directly address the challenges of taking genomics into clinical research for the development of therapeutics and companion diagnostics. By providing patient-centric data and analysis, we facilitate biomarker-driven research that can accelerate the process of translational drug discovery." Mr. Akhtari concluded, "With the growing availability and decreasing cost of obtaining individual patient data moving genomics into clinical applications, NextBio Clinical is a natural extension for both our platform and our clients who have been using NextBio in their research for many years." Applying Genomics to Translational Medicine NextBio Clinical aggregates and correlates terabyte-scale collections of private and public cross-platform 'omics' data, experimental data from cell lines and other sources, and clinical data from individual patients and population studies. Controlled vocabularies and the platform's semantic framework eliminate confounding gene, disease and compound annotations, facilitating applications of this content at all stages of research, from early stage experimentation to repositioning approved drugs.
"With efforts such as The Cancer Genome Atlas, the International Cancer Genome Consortium and others, the growth of patient-level data in the public domain has been enormous. Simultaneously, efforts like the Cancer Cell Line Encyclopedia are transforming our understanding of pharmacogenomics with cell line models. We are excited about the potential of integrating these diverse data within the framework of NextBio Clinical," said Ilya Kupershmidt, co-founder and Vice President of Products at NextBio.
Organizations can use the NextBio Clinical platform to accelerate drug discovery by applying human biology earlier in the discovery process, to discover and develop predictive biomarkers, and to optimize clinical trial design and patient selection to reduce development timelines and increase the chance of successful approval for new therapies.
Mr. Kupershmidt added, "By enabling our users to bring patient genomic data into the clinical development process at an early stage, we hope to help improve the pace and success rate at which biomarker-based therapeutics are approved for clinical use." NextBio Clinical at Bio-IT World 2012 Ilya Kupershmidt, Co-founder and VP of Products at NextBio, will describe NextBio Clinical in his talk at Bio-IT World 2012, titled "Patient-centered solutions for translational medicine" on Wednesday April 25, 2012 from 3:00-3:15 p.m. The meeting is being held in Boston, MA at the World Trade Center from April 24-26.
NextBio representatives are also available for additional information or product demos at Booth 326 in the exhibit hall.
About NextBio NextBio provides a state of the art scientific platform to aggregate and interpret large quantities of genomic and other life sciences data for research and clinical applications. NextBio's platform integrates data from multiple repositories and diverse technologies by means of a unique correlation engine, which pre-computes billions of significant connections between disparate public and proprietary sources of clinical and experimental data. In doing so, the platform enables a seamless interoperability from instrument readouts to data interpretation for translational research and discovery. Backed by highly scalable, Big Data technology capable of analyzing petabytes of data in real-time, NextBio's platform is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.
Today, NextBio is used by researchers and clinicians in over 40 top commercial and academic institutions including the University of Southern California, Sanford-Burnham Medical Research Institute, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, University of California at Berkeley Takeda and many others. To learn more about NextBio, please visit our website at http://www.nextbio.com.
CONTACT: NextBio Saeid Akhtari President and CEO email@example.com or Kureczka/Martin Associates Joan Kureczka, 415-821-2413 Mobile: 415-690-0210 Joan@Kureczka-Martin.com KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS PHARMACEUTICAL SOURCE: NextBio Copyright Business Wire 2012 PUB: 04/23/2012 08:01 AM/DISC: 04/23/2012 08:01 AM http://www.businesswire.com/news/home/20120423005380/